Search

Mission ‘Gene Therapy’ for Horizon Europe

Mission ‘Gene Therapy’ for Horizon Europe

Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.

Read more

Nikolai Klimko 1956-2023

Professor Nikolai Klimko 

Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023

With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.

Read more

Chairs and Members

The EHA SWG commenced in 2020, but initial work was delayed due to the COVID-19 pandemic. We therefore started in 2021, in preparation for a (successful) SWG meeting in 2022.

Read more

EU Calls for Proposal 2022

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

Speaker Guidelines

On this page you can find the detailed instructions for your abstract and presentation, as referred to in the Confirmation email.

Read more

Mission

The European Hematology Association (EHA) promotes excellence in patient care, research, and education in hematology.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Registration

Register here

The registration fee for the ESH-EBMT-EHA 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Read more